A new study published online in the Journal of Cutaneous Medicine and Surgery shows that the combination, topical therapy 3% erythromycin/5% benzoyl peroxide, commonly known as Benzamycin®, may provide a greater beneficial effect than 0.025% tretinoin/4% erythromycin in the treatment of moderate facial acne.
A summary of this study can be accessed by logging onto http://link.springer-ny.com/link/service/journals/10227/index.htm.
“Our findings demonstrate that the combination found in Benzamycin® is more effective than Stievamycin® in the treatment of facial acne,” said Aditya K. Gupta, M.D., Ph.D., F.R.C.P.C., Associate Professor, Division of Dermatology, Department of Medicine, Sunnybrook and Women’s College Health Sciences Center and the University of Toronto, and lead author of the study.
Resistance to antibiotic agents is increasing in P. acnes strains. Combination treatments have been investigated to combat this problem. Medications with different mechanisms of action may exhibit a synergistic response against the bacteria, producing greater effect than a single agent alone, such as Benzamycin, a combination of erythromycin (antibiotic) and benzoyl peroxide (anti-microbial). Clinical studies have shown that Benzamycin can produce improvements in mild to moderate acne in as little as two weeks when compared to either medication used alone.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!